|
PL220721B1
(pl)
*
|
2001-03-29 |
2015-12-31 |
Lilly Co Eli |
Związki będące pochodnymi N-(indolilo-2-etylo) benzyloaminy, kompozycja farmaceutyczna oraz zastosowanie
|
|
EP1411925A1
(en)
*
|
2001-08-03 |
2004-04-28 |
PHARMACIA & UPJOHN COMPANY |
5-arylsulfonyl indoles having 5-ht6 receptor affinity
|
|
WO2004000849A2
(en)
|
2002-06-21 |
2003-12-31 |
Suven Life Sciences Limited |
Tetracyclic arylsulfonyl indoles having serotonin receptor affinity
|
|
NZ537635A
(en)
*
|
2002-07-17 |
2006-11-30 |
Lek Pharmaceuticals D |
Novel derivatives of pyridylethanol (phenylethyl) amines as inhibitors of cholesterol biosynthesis, processes for their preparation, and pharmaceutical compositions containing them
|
|
US7381719B2
(en)
|
2002-09-19 |
2008-06-03 |
Eli Lilly And Company |
Diaryl ethers as opioid receptor antagonist
|
|
AU2003299227A1
(en)
*
|
2002-12-20 |
2004-07-14 |
Ciba Specialty Chemicals Holding Inc. |
Synthesis of amines and intermediates for the synthesis thereof
|
|
US7396943B2
(en)
|
2003-03-07 |
2008-07-08 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
BRPI0407616A
(pt)
|
2003-03-07 |
2006-02-14 |
Lilly Co Eli |
composto, composição farmacêutica, método para bloquear uma combinação de receptor de mu, capa, delta (heterodìmero) deste em mamìferos, método para tratar ou prevenir obesidade e doenças relacionadas, uso de um composto, e método de suprimir o apetite em um paciente em necessidade deste"
|
|
DE10320782A1
(de)
*
|
2003-05-09 |
2004-11-25 |
Bayer Cropscience Ag |
Substituierte Oxyarene
|
|
DE602004000260T2
(de)
|
2003-07-22 |
2006-08-24 |
Arena Pharmaceuticals, Inc., San Diego |
Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
|
|
US7414132B2
(en)
|
2003-12-22 |
2008-08-19 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
US7381750B2
(en)
|
2004-03-12 |
2008-06-03 |
Eli Lilly And Company |
Amino-phenoxymethyl-benzamide opioid receptor antagonists
|
|
CA2557794A1
(en)
|
2004-03-15 |
2005-10-06 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
EP1751103B1
(en)
|
2004-03-15 |
2009-01-14 |
Eli Lilly And Company |
4-(5-(aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
|
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
|
CA2810655C
(en)
*
|
2004-06-24 |
2013-12-10 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
|
EP1632491A1
(en)
*
|
2004-08-30 |
2006-03-08 |
Laboratorios Del Dr. Esteve, S.A. |
Substituted indole compounds and their use as 5-HT6 receptor modulators
|
|
CN101023074B
(zh)
*
|
2004-09-22 |
2012-10-10 |
詹森药业有限公司 |
Mdm2及p53间相互作用的抑制剂
|
|
US7459469B2
(en)
|
2004-11-10 |
2008-12-02 |
Targacept, Inc. |
Hydroxybenzoate salts of metanicotine compounds
|
|
DE102004062542A1
(de)
*
|
2004-12-24 |
2006-07-06 |
Bayer Cropscience Ag |
Substituierte Oxyarene
|
|
RS55940B1
(sr)
|
2005-12-28 |
2017-09-29 |
Vertex Pharma |
Čvrsti oblici n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida
|
|
WO2007074860A1
(ja)
*
|
2005-12-28 |
2007-07-05 |
Sekisui Medical Co., Ltd. |
凝集測定用試薬及び凝集測定方法
|
|
US20090076064A1
(en)
*
|
2006-01-06 |
2009-03-19 |
Astrazeneca Ab |
Compounds
|
|
JP5162574B2
(ja)
|
2006-03-22 |
2013-03-13 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Ｍｄｍ２及びｐ５３間の相互作用のインヒビターとしての環式アルキルアミン誘導体
|
|
WO2007107543A1
(en)
|
2006-03-22 |
2007-09-27 |
Janssen Pharmaceutica N.V. |
Inhibitors of the interaction between mdm2 and p53
|
|
TWI389889B
(zh)
|
2006-05-09 |
2013-03-21 |
Targacept Inc |
（２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
|
|
EP2357174A1
(en)
|
2006-05-09 |
2011-08-17 |
AstraZeneca AB |
Salt forms of (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-penten-2-amine
|
|
EP1953153A1
(en)
*
|
2007-01-31 |
2008-08-06 |
Laboratorios del Dr. Esteve S.A. |
Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
|
|
EP2185541B1
(en)
|
2007-08-06 |
2015-01-28 |
Janssen Pharmaceutica, N.V. |
Substituted phenylenediamines as inhibitors of the interaction between MDM2 and p53
|
|
JO2704B1
(en)
|
2007-09-21 |
2013-03-03 |
جانسين فارماسوتيكا ان في |
Interference inhibition factors between MD2 and B53
|
|
US20090093513A1
(en)
*
|
2007-10-09 |
2009-04-09 |
Hamann Mark T |
Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter
|
|
AU2008331920A1
(en)
*
|
2007-12-04 |
2009-06-11 |
Merck Sharp & Dohme Corp. |
Tryptamine sulfonamides as 5-HT6 antagonists
|
|
EP2254564A1
(en)
|
2007-12-12 |
2010-12-01 |
Glaxo Group Limited |
Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
|
|
WO2009102805A1
(en)
*
|
2008-02-11 |
2009-08-20 |
Organix Inc. |
Indole compounds and methods of use thereof
|
|
WO2009123714A2
(en)
|
2008-04-02 |
2009-10-08 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
US12458635B2
(en)
|
2008-08-13 |
2025-11-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
|
US9126946B2
(en)
|
2008-10-28 |
2015-09-08 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
|
|
ES2639752T3
(es)
*
|
2009-02-04 |
2017-10-30 |
Janssen Pharmaceutica N.V. |
Inhibidores de la interacción entre MDM2 y p53
|
|
SG193156A1
(en)
|
2009-03-20 |
2013-09-30 |
Vertex Pharma |
Process for making modulators of cystic fibrosis transmembrane conductance regulator
|
|
JP5083256B2
(ja)
*
|
2009-03-20 |
2012-11-28 |
株式会社デンソー |
半導体装置およびその製造方法
|
|
EP2464227A4
(en)
*
|
2009-08-10 |
2013-02-20 |
Galenea Corp |
COMPOUNDS AND METHODS OF USE
|
|
EP2311823A1
(en)
|
2009-10-15 |
2011-04-20 |
AC Immune S.A. |
2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
|
|
TW201139370A
(en)
*
|
2009-12-23 |
2011-11-16 |
Lundbeck & Co As H |
Processes for the manufacture of a pharmaceutically active agent
|
|
FR2961097B1
(fr)
*
|
2010-06-09 |
2012-07-13 |
Oreal |
Procede cosmetique de traitement des odeurs corporelles humaines utilisant un compose 6-alkoxy tryptamine
|
|
FR2961095B1
(fr)
*
|
2010-06-09 |
2012-06-15 |
Oreal |
Composition cosmetique et/ou dermatologique comprenant au moins un compose 6-alcoxy tryptamine
|
|
US8293218B2
(en)
*
|
2010-07-29 |
2012-10-23 |
Conopco, Inc. |
Skin care compositions comprising substituted monoamines
|
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
WO2014165701A1
(en)
*
|
2013-04-03 |
2014-10-09 |
The University Of Utah Research Foundation |
Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
|
|
BR112014021090B1
(pt)
|
2012-02-27 |
2023-01-24 |
Vertex Pharmaceuticals Incorporated |
Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma
|
|
MX2014011315A
(es)
*
|
2012-03-20 |
2014-10-17 |
Adamed Sp Zoo |
Derivados de sulfonamida de bencilamina para el tratamiento de enfermedades del sistema nervioso central.
|
|
CN102746211B
(zh)
*
|
2012-06-27 |
2015-05-27 |
上海泰坦化学有限公司 |
一种取代吲哚-3-甲醛类化合物的制备方法
|
|
JO3459B1
(ar)
*
|
2012-09-09 |
2020-07-05 |
H Lundbeck As |
تركيبات صيدلانية لعلاج مرض الزهايمر
|
|
EP3610890A1
(en)
|
2012-11-14 |
2020-02-19 |
The Johns Hopkins University |
Methods and compositions for treating schizophrenia
|
|
CN104725249B
(zh)
*
|
2013-12-20 |
2019-02-12 |
广东东阳光药业有限公司 |
苄胺类衍生物及其在药物上的应用
|
|
JO3639B1
(ar)
*
|
2014-07-04 |
2020-08-27 |
H Lundbeck As |
صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
|
|
EP3204358B1
(en)
|
2014-10-07 |
2018-09-19 |
Vertex Pharmaceuticals Incorporated |
Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
|
|
ES2570452B1
(es)
*
|
2014-10-15 |
2017-04-19 |
Fundación Para La Investigación Biomédida Del Hospital Universitario De La Princesa |
Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas
|
|
CN105175307A
(zh)
*
|
2014-11-18 |
2015-12-23 |
苏州晶云药物科技有限公司 |
Lu AE58054的盐酸盐晶型A及其制备方法和用途
|
|
TW201630881A
(zh)
|
2014-12-12 |
2016-09-01 |
Ｈ 朗德貝克公司 |
用於生產艾達魯吡啶之方法
|
|
CN104529865B
(zh)
*
|
2014-12-12 |
2017-02-01 |
广东东阳光药业有限公司 |
苄胺类衍生物及其在药物上的应用
|
|
RU2017145976A
(ru)
|
2015-06-12 |
2019-07-15 |
Аксовант Сайенсиз Гмбх |
Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
|
|
TW201720439A
(zh)
|
2015-07-15 |
2017-06-16 |
Axovant Sciences Gmbh |
用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物
|
|
WO2017067670A1
(en)
|
2015-10-23 |
2017-04-27 |
Pharmathen S.A. |
A novel process for the preparation of tryptamines and derivatives thereof
|
|
EP3440055B1
(en)
*
|
2016-04-08 |
2020-03-11 |
H. Lundbeck A/S |
A process for the manufacture of idalopirdine via hydrogenation of an imine
|
|
MX387444B
(es)
*
|
2016-04-26 |
2025-03-18 |
H Lundbeck As |
Uso de un inhibidor de la acetilcolinesterasa e idalopirdina para reducir las caidas en pacientes con la enfermedad de parkinson
|
|
US10864191B2
(en)
|
2016-05-11 |
2020-12-15 |
H. Lundbeck A/S |
5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
|
|
WO2018013686A1
(en)
*
|
2016-07-12 |
2018-01-18 |
Concert Pharmaceuticals, Inc. |
Deuterated idalopirdine
|
|
EP3333154A1
(en)
|
2016-12-07 |
2018-06-13 |
Sandoz Ag |
Crystalline form of a selective 5-ht6 receptor antagonist
|
|
CN106632303A
(zh)
*
|
2017-01-09 |
2017-05-10 |
湖南华腾制药有限公司 |
一种6‑噻唑基吲哚衍生物的制备方法
|
|
WO2018191146A1
(en)
*
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
|
JP7167065B2
(ja)
|
2017-05-24 |
2022-11-08 |
ハー・ルンドベック・アクチエゼルスカベット |
Ａｐｏｅ４アレルを有する患者亜集団におけるアルツハイマー病の治療での使用のための５－ｈｔ６受容体アンタゴニストとアセチルコリンエステラーゼ阻害剤の組み合わせ
|
|
EP3706727B1
(en)
*
|
2017-11-06 |
2024-07-31 |
Acelot, Inc. |
Small molecule drugs and related methods for treatment of diseases related to a 42 oligomer formation
|
|
CN113543852A
(zh)
|
2019-03-06 |
2021-10-22 |
第一三共株式会社 |
吡咯并吡唑衍生物
|
|
CN109942527A
(zh)
*
|
2019-04-26 |
2019-06-28 |
新乡市润宇新材料科技有限公司 |
一种3-溴二苯并呋喃的合成方法
|
|
JP7655943B2
(ja)
|
2020-05-08 |
2025-04-02 |
サイレラ インコーポレイテッド |
新規な組成物および医薬組成物
|
|
US12240813B2
(en)
|
2020-05-19 |
2025-03-04 |
Cybin Irl Limited |
Deuterated tryptamine derivatives and methods of use
|
|
EP4208446A4
(en)
*
|
2020-09-02 |
2024-10-30 |
Enveric Biosciences Canada Inc. |
PSILOCYBIN NITROGEN DERIVATIVES AND ASSOCIATED USE FOR THE MODULATION OF THE 5-HT2A RECEPTOR AND FOR THE TREATMENT OF A PSYCHIATRIC DISORDER
|
|
EP4291549A4
(en)
*
|
2021-02-12 |
2025-01-22 |
Enveric Biosciences Canada Inc. |
MULTISUBSTITUENT PSILOCYLYBINDER DERIVATIVES AND METHODS OF USE
|
|
US20240166599A1
(en)
*
|
2021-03-02 |
2024-05-23 |
Mindset Pharma Inc. |
Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
|
|
WO2022241006A1
(en)
*
|
2021-05-11 |
2022-11-17 |
Saint Joseph's University |
Selective, partial, and arrestin-biased 5-ht2a agonists with utility in various disorders
|
|
IL308816A
(en)
|
2021-05-25 |
2024-01-01 |
Atai Therapeutics Inc |
New n,n-dimethyltryptamine salts and crystalline salt forms
|
|
JP2024520832A
(ja)
*
|
2021-06-08 |
2024-05-24 |
エンセオジェニックス バイオサイエンシズ， インコーポレイテッド |
セロトニン受容体のジメトキシフェニルアルキルアミン活性化剤
|
|
IL309210A
(en)
|
2021-06-09 |
2024-02-01 |
Atai Therapeutics Inc |
Parent drugs and conjugates of dimethyltryptamine
|
|
WO2023044577A1
(en)
*
|
2021-09-24 |
2023-03-30 |
Psygen Inc. |
Recovery method for tryptamines
|
|
AU2022425198A1
(en)
|
2021-12-27 |
2024-07-18 |
Atai Therapeutics, Inc. |
Aminotetraline activators of serotonin receptors
|
|
JP2024545787A
(ja)
|
2021-12-30 |
2024-12-11 |
アタイ セラピューティクス， インコーポレイテッド |
一酸化窒素送達剤としてのジメチルトリプタミン類似体
|
|
US12065404B2
(en)
|
2022-03-18 |
2024-08-20 |
Enveric Biosciences Canada Inc. |
C4-carboxylic acid-substituted tryptamine derivatives and methods of using
|
|
WO2024229149A1
(en)
|
2023-05-01 |
2024-11-07 |
Atai Therapeutics Inc. |
Compositions and methods for treatment of diseases and disorders
|
|
US20250243160A1
(en)
*
|
2024-01-24 |
2025-07-31 |
Automera PTE. LTD |
Indole derivatives for targeting autophagy
|